Astronomers Uncover a Massive Shaft of Missing Matter
Another clue about the whereabouts of the missing matter in the Universe has just emerged from amid the largest local cosmic structure.
X-ray observations have revealed a massive filament of hot gas, measuring some 23 million light-years in length, in the space between four sub-clusters of galaxies in the enormous, 8,000-galaxy strong Shapley Supercluster.
"For the first time, our results closely match what we see in our leading model of the cosmos – something that's not happened before," says astrophysicist Konstantinos Migkas of Leiden Observatory in the Netherlands. "It seems that the simulations were right all along."
Most matter in the Universe comprises of a 'dark' variety we can't easily identify. Only around 15 percent of matter exists in the form of far more familiar protons, neutrons and electrons – what we might call 'normal matter'.
We know more or less how much normal matter there was in the early Universe, just after the Big Bang, thanks to the Cosmic Microwave Background, the fossil radiation that propagated through space-time when the Universe became transparent.
A huge problem arises when we compare that early Universe quantity of normal matter to the amount that's around now. All the stars, black holes, galaxies, planets, dust, gas, and everything else we can see only accounts for around half of what we'd expect to find. Matter can't be destroyed, so where the heck did it go?
The best explanation we have is that it ended up in intergalactic space – vast amounts of material so tenuously distributed along the cosmic web that we can't directly see it. Increasing evidence of this faint reservoir has been emerging for the last few years; and the discovery of this filament is some of the best evidence yet.
RELATED: Half The Universe's Matter Was Missing. Astronomers Just Found It.
The cosmic web is a vast network of filaments of dark matter that span intergalactic space, connecting galaxies and acting as a "superhighway" along which galaxies and matter are funneled. We can't see these filaments easily, but Migkas and his team identified one by comparing observations from two X-ray telescopes.
The now-retired Suzaku X-ray telescope was excellent for observing faint X-radiation that is spread over a large surface area, while XMM-Newton can pick out point sources of very bright X-rays. The researchers used existing images taken by the former to detect the glow of gas within the filament, while observations from the latter allowed them to remove contaminating X-rays from sources such as black holes.
The resulting structure is a beast, stretching between two pairs of galaxy clusters named A3528S/N and A3530/32. Along its 23 million-light-year length, it contains enough material to fill 10 Milky Way galaxies, blazing at a temperature of more than 10 million degrees Celsius.
It is, the researchers say, exactly what such a filament is expected to be, based on simulations of the Universe.
"This research is a great example of collaboration between telescopes, and creates a new benchmark for how to spot the light coming from the faint filaments of the cosmic web," says astronomer and XMM-Newton project scientist Norbert Schartel of the European Space Agency.
"More fundamentally, it reinforces our standard model of the cosmos and validates decades of simulations: it seems that the 'missing' matter may truly be lurking in hard-to-see threads woven across the Universe."
The research has been published in Astronomy & Astrophysics.
Our Galaxy's Monster Black Hole Is Spinning Almost as Fast as Physics Allows
Did a Passing Star Cause Earth to Warm 56 Million Years Ago?
A Game-Changing Telescope Is About to Drop First Pics. Here's How to Watch.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
23 minutes ago
- Medscape
EMA Recommends Rezdiffra for MASH Liver Fibrosis
The European Medicines Agency (EMA) has recommended conditional marketing authorization for Rezdiffra (resmetirom) for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis. MASH was formerly known as nonalcoholic fatty liver disease (NASH). There are currently no authorized treatments for MASH in the EU, making Rezdiffra a potential first. MASH is a serious liver disease that occurs when fat accumulates in the liver, causing inflammation. Left untreated, it can lead to cirrhosis and cancer. Symptoms may only present in more advanced stages of the condition, at which point they may include discomfort or pain in the upper right abdomen, muscle weakness or loss, and swelling in the abdomen or legs. Estimates suggest that up to 5% of people in Europe have MASH and that around 25% have metabolic dysfunction‐associated steatotic liver disease (MASLD), the condition that precedes MASH. MASLD was previously known as nonalcoholic fatty liver disease (NAFLD). The active substance of Rezdiffra is resmetirom, which is a partial agonist of the thyroid hormone receptor-beta. It works by promoting lipophagy and hepatic fatty acid beta-oxidation to reduce liver fat, inflammation, and liver fibrosis. The EMA's decision comes after interim results from a pivotal, ongoing phase 3 trial including 966 adults with biopsy-confirmed MASH with varying stages of fibrosis. Patients were randomly assigned treatment on a 1:1:1 ratio to receive once-daily resmetirom at 80 mg or 100 mg, or a placebo. The primary endpoints were MASH resolution at week 52 with no worsening of fibrosis, and a reduction in fibrosis by at least one stage alongside no worsening of NAFLD activity score. MASH resolution included a reduction in the NAFLD activity score by ≥ 2 points. Scores range from 0 to 8; higher scores indicate more severe disease. After 12 months, 30% of patients in the 100 mg resmetirom group and 26% of those in the 80 mg group achieved MASH resolution with no worsening fibrosis compared with 10% in the placebo group. Meanwhile, 26% of patients in the 100 mg resmetirom group and 24% of patients in the 80 mg group experienced fibrosis improvement by at least one stage with no worsening of NAFLD activity score compared with 14% in the placebo group. The most frequent side effects were diarrhea, nausea, itching, and pruritus. Diarrhea and nausea were more frequent among those taking resmetirom than those taking the placebo. The rate of serious adverse events was similar across all groups and ranged from 10.9% to 12.7%. Rezdiffra will be available as 60 mg, 80 mg, and 100 mg film-coated tablets. It should be taken alongside diet and exercise. The opinion adopted by the EMA will now go to the European Commission to await a decision on EU-wide marketing authorization. In the meantime, the EMA has required Rezdiffra's applicant to complete both the pivotal and another ongoing trial to provide further data regarding the drug's efficacy. This conditional approval comes as the EMA perceives that the benefits to patients from immediate availability outweigh the risk inherent in incomplete data. Detailed recommendations for using Rezdiffra will be described in the summary of product characteristics, which will be published on the EMA website in all official European Union languages.
Yahoo
3 hours ago
- Yahoo
London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape
Many biotechnology companies are navigating the various obstacles prevalent within the pharmaceutical industry with the implementation of artificial intelligence (AI) and machine learning (ML) technologies to optimise and streamline processes within the drug development landscape, according to speakers from the London biotechnology conference in London, UK, on 18-19 June 2025. In recent years, the pharmaceutical industry has exhibited a significant shift into digitalisation, with AI pushing for innovation across the entire drug development value chain, from accelerating drug discovery to optimising clinical trial design to ultimately improve patient outcomes. Novo Nordisk has taken initiatives to accelerate target discovery by implementing AI/ML technologies into genetic and human-centric in vitro models. Given the significant costs associated with drug discovery and development, achieving a successful drug candidate remains a major challenge. This complex process involves different processes such as target identification and validation, lead optimisation, and lengthy clinical trials. According to one of Novo Nordisk's speakers at the London Biotechnology conference, the company aims to utilise human data input, such as genetics, samples, and multiomics from a variety of diverse patient populations, into its target discovery engine. The AI-driven engine utilises data mining and analyses linking specific diseases to novel targets to ultimately increase the number of new targets aimed to reach the first human dose. In addition, Novo Nordisk has implemented cell image foundational models driven by deep learning to increase screening throughput derived from extensive sets of genomic data. The usage of AI and deep learning tools within the virtual assay enables large image datasets of cells to be translated into text, allowing effective mapping of the various cells by their morphology, enabling researchers to gain an understanding and effectively predict the characteristics of the cells. The implementation of AI-driven technologies has the potential to streamline many aspects of the drug development value chain, from enabling standardisation of datasets across functionalities to accelerating in vitro and in silico models and tools. As a result, pharmaceutical organisations can scale their methodologies whilst simultaneously increasing output to ultimately improve patient outcomes. "London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio


Medscape
3 hours ago
- Medscape
HIV Prevention Vaginal Ring Recommended for 16-Year-Olds
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an extension of indication for dapivirine vaginal ring 25 mg to include its use in women from 16 years of age. The EMA said there had been some uncertainties about the risk for resistance and the benefits in younger women, which needed to be addressed. Upon further study, the ring was shown to be moderately effective at lowering the risk for HIV-1 infection following vaginal intercourse, with its side effects considered manageable. As such, the EMA decided that its benefits outweigh the risks in women who are not using oral pre-exposure prophylaxis (PrEP). The dapivirine ring was originally approved in July 2020 to reduce the risk for HIV-1 infection in women 18 years and older through vaginal intercourse, when taking PrEP medicines by mouth was not feasible. It is the first long-acting technology approved for HIV prevention in women and is intended for use outside the EU. The device was submitted under a regulatory procedure, EU- Medicines for all (EU-M4All) that enables the EMA, in collaboration with the World Health Organization (WHO), to provide scientific opinions on high priority human medicines that are intended for markets outside the EU. The process allows the European agency to support global regulatory capacity building and contributes to the protection and promotion of public health beyond the EU. Its overall aim is to facilitate access to essential medicines in low- and middle-income countries that are intended to prevent or treat diseases of major public health interest. The flexible silicone ring is inserted in the vagina for a period of 28 days, after which it should be replaced by a new one. It works by slowly releasing dapivirine over the course of a month, which blocks the ability of HIV to make copies of itself inside healthy cells. It can be inserted and removed by the user. A study conducted in almost 2000 women in sub-Saharan Africa showed that dapirivine vaginal ring 25 mg lowered the chances of being infected with HIV by more than one third over the course of 24 months compared with the placebo group. It was first developed by the International Partnership for Microbicides and since acquired by the Population Council in 2022. It was first approved in 2021 by the Medicines Control Authority of Zimbabwe and has since been approved in several additional African countries. The ring has been on the WHO's prequalification list of medicines since November 2020 following positive scientific opinion from the EMA. The WHO has said it is intended to reduce the risk of acquiring HIV during vaginal sex for women who are at substantial HIV risk as a complementary prevention approach in addition to other safer-sex practices. The CHMP's opinion to extend the indication for this medicine to include its use in women from 16 years of age expands the HIV prevention choice beyond condoms and oral PrEP and could be an important tool to protect younger women from becoming HIV-positive.